We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+18.5%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.93B
AUM Growth
+$31.2M
Cap. Flow
+$169M
Cap. Flow %
8.75%
Top 10 Hldgs %
45.68%
Holding
151
New
31
Increased
40
Reduced
42
Closed
31

Top Buys

Rank Stock Value
1
ENSG icon
The Ensign Group
ENSG
+$104M
2
EHC icon
Encompass Health
EHC
+$86.2M
3
CTRE icon
CareTrust REIT
CTRE
+$42.1M
4
UNH icon
UnitedHealth
UNH
+$19M
5
INSM icon
Insmed
INSM
+$18.1M

Top Sells

Rank Stock Value
1
GSK icon
GSK
GSK
+$68.9M
2
NTRA icon
Natera
NTRA
+$44.5M
3
DOC icon
Healthpeak Properties
DOC
+$32.5M
4
AVTR icon
Avantor
AVTR
+$23.3M
5
QGEN icon
Qiagen
QGEN
+$20.3M

Sector Composition

Rank Sector Weight
1 Healthcare 89.53%
2 Real Estate 5.59%
3 Miscellaneous 4.84%
4 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UNH icon
26
UnitedHealth
UNH
$356B
$21.3M 1.1%
+51,145
New +$19M
WELL icon
27
Welltower
WELL
$170B
$19.8M 1.03%
87,312
-93,641
-52% -$19.8M
BBNX
28
Beta Bionics
BBNX
$874M
$19.6M 1.02%
1,249,441
-165,397
-12% -$1.97M
COGT icon
29
Cogent Biosciences
COGT
$6.03B
$19M 0.98%
+490,235
New +$17.2M
BCRX icon
30
BioCryst Pharmaceuticals
BCRX
$2.55B
$18.7M 0.97%
1,865,653
-1,174,167
-39% -$10.6M
MOH icon
31
Molina Healthcare
MOH
$10.5B
$18.4M 0.96%
80,594
+47,783
+146% +$8.66M
PNTG icon
32
Pennant Group
PNTG
$1.33B
$17M 0.88%
460,272
+148,094
+47% +$4.84M
LTC
33
LTC Properties
LTC
$2.22B
$16.2M 0.84%
420,640
+99,594
+31% +$3.78M
INSM icon
34
Insmed
INSM
$27.6B
$15.9M 0.83%
+149,209
New +$18.1M
VRDN icon
35
Viridian Therapeutics
VRDN
$2.6B
$15.3M 0.79%
831,142
+117,873
+17% +$1.9M
BMRN icon
36
BioMarin Pharmaceuticals
BMRN
$12.9B
$14.3M 0.74%
249,607
+41,839
+20% +$2.29M
AMN icon
37
AMN Healthcare
AMN
$1.31B
$13.9M 0.72%
+428,531
New +$11.1M
CELC icon
38
Celcuity
CELC
$4.68B
$13.4M 0.69%
+127,931
New +$14.8M
PHVS icon
39
Pharvaris
PHVS
$2.47B
$13.4M 0.69%
386,383
-20,577
-5% -$623K
CTMX icon
40
CytomX Therapeutics
CTMX
$808M
$13.3M 0.69%
3,558,497
+369,983
+12% +$1.41M
HUM icon
41
Humana
HUM
$48.2B
$12.4M 0.64%
+31,171
New +$8.87M
XENE icon
42
Xenon Pharmaceuticals
XENE
$5.79B
$11.9M 0.62%
196,532
+66,958
+52% +$3.72M
CRVS icon
43
Corvus Pharmaceuticals
CRVS
$1.21B
$11.2M 0.58%
+747,994
New +$10.4M
ASND icon
44
Ascendis Pharma A/S
ASND
$17.7B
$11.1M 0.58%
+41,621
New +$9.72M
BRKR icon
45
Bruker
BRKR
$8.91B
$11M 0.57%
182,894
+65,881
+56% +$3.07M
MRNA icon
46
Moderna
MRNA
$58.1B
$10.7M 0.55%
152,122
-7,586
-5% -$392K
GPCR icon
47
Structure Therapeutics
GPCR
$3.38B
$10.5M 0.55%
196,302
+58,266
+42% +$2.58M
INSM icon
48
CALL
Insmed
INSM
$27.6B
$10.3M 0.53%
96,600
+2,600
+3% +$315K
DFTX
49
Definium Therapeutics
DFTX
$5.12B
$10.2M 0.53%
217,185
+56,462
+35% +$1.4M
CMPS
50
Compass Pathways
CMPS
$1.84B
$9.52M 0.49%
672,825
-5,099
-0.8% -$51.8K
1
2
3 4 5

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Eversept Partners held 151 positions worth $1.93B, up 1.6% from $1.9B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Eversept Partners deployed $169M of net new capital in Q2 2026, opening 31 new positions and adding to 40 existing holdings. Its largest new stake was CareTrust REIT: 1,072,015 shares worth $43.3M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 74% a quarter earlier, followed by Real Estate and Miscellaneous.

On the sell side, the largest reduction was GSK, an estimated $68.9M trimmed.

  • Eversept Partners's largest Q2 2026 buy was CareTrust REIT: 1,072,015 shares worth $43.3M.
  • Eversept Partners added most to The Ensign Group in Q2 2026, an estimated $104M increase.
  • Eversept Partners's biggest Q2 2026 reduction was GSK, cutting an estimated $68.9M.
  • Eversept Partners fully exited Healthpeak Properties in Q2 2026, selling an estimated $32.5M.
  • Eversept Partners's ten largest holdings make up 46% of its $1.93B portfolio in Q2 2026.
  • Eversept Partners opened 31 new positions and closed 31 in Q2 2026.
  • Eversept Partners's portfolio value rose 1.6% quarter-over-quarter to $1.93B.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.